Crucell Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

1. [verwijderd] 1 september 2006 13:42

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Published online: 1 September 2006; | doi:10.1038/news060828-6
   Semen aggravates cervical cancer
   Advice for condom use gets an extra boost.
   Richard Van Noorden
   
   Deciding not to use a condom can have a host of potentially negative side effects: including, scientists now say, aggravating cancer.
   
   Researchers have shown that semen contains a huge dose of hormones that boosts blood vessel growth, and that cancerous cells in a woman's uterus or cervix have a high level of receptors for these hormones. The combination could prove dangerous for women at high risk of getting cancer or those already with early-stage cancer, they say.
   The finding lends weight to campaigns promoting condom use, particularly in African and South American countries, where cervical cancer is most common.
   Henry Jabbour's team of researchers at the Medical Research Council's Human Reproductive Sciences Unit in Edinburgh, UK, together with scientists from the University of Cape Town, South Africa, took a look at prostaglandins — hormones that are produced naturally in the body, including by female reproductive organs. These hormones are known to help control the immune system and regulate cell growth.
   In 2004, Jabbour and his colleagues showed that levels of prostaglandin receptors are often increased in cervical and uterine cancerous tumour cells1. "We still don't know why that happens," Jabbour admits.
   Seminal fluid contains a concentration of prostaglandins that is a thousand times greater than is present around female reproductive cells. "That is a massive dose compared to normal physiological levels," says Jabbour. So the team investigated what happens when this flood of hormones hits cancerous cells.
   
   Double protection
   
   The team took a standard line of cancer cells and added prostaglandin receptors up to the levels seen in cervical cancers. They then added semen, and watched to see what the prostaglandin would do. As expected, it activated genes in the cancer cells that contribute to blood vessel growth, they report in Endocrinology2. In a patient, this would increase tumour size. The same thing happened with cells taken from women diagnosed with uterine cancer, they report in Human Reproduction3.
   There's a positive feedback effect too," says Jabbour. "The enzymes that make prostaglandins in female reproductive cells are also upregulated, so yet more prostaglandins will be created."
   However, the researchers don't know what effect it might have on testicular cancer.
   Cervical cancer is most common in women who live in the developing world. It is usually triggered by the sexually transmitted human papilloma virus; so it is already advised to use a condom to lower cancer risk.
   Now it seems that semen can worsen cancer too. Jabbour advises that "sexually active women who are at risk of cervical or uterine cancer should encourage their partners to wear a condom."
   Jabbour adds that blocking prostaglandin receptors might be a potential approach for cervical cancer therapy. "That would tackle both possible sources of prostaglandin - those produced naturally by women and those introduced to the body by sperm."
   www.nature.com/news/2006/060828/full/...
   *******************
   Annual shortage of over 15 billion condoms
   The world is faced with an annual shortage of 15 billion condoms for the combat against HIV/ AIDS. Only six to nine billion condoms are available, whereas 24 billion are needed. In Africa, where the epidemic is the gravest, this means that only three condoms per man are obtainable. That is too few, especially in cultures where men are not monogamous. This was said by Helen Rees, AIDS researcher at the University of Witwaterstrand, Johannesburg, South Africa, today at the AIDS Vaccine 06 conference in the RAI in Amsterdam.
   Due to the great scarcity of condoms women increasingly are infected with the virus. ‘Of the 24 year old ladies in South Africa 26% is infected while among men of the same age this is only 11%’, said Rees. At the age of 11 the infection rate is still equal among boys and girls.
   In order to fight the HIV/AIDS pandemic, worldwide an additional annual amount of 3 billion dollars is needed for research and prevention. As a result, the majority of the goals to combat HIV/AIDS, cannot be met.
   With respect to the sexual intercourse between men and women ‘safe sex’ has the largest effect in adultery. The influence of safe sex during adultery is many times larger than the dissemination through, for example, prostitutes.
   Media Information
   The AIDS Vaccine 06 conference takes place up to and including 1 September in the RAI in Amsterdam, The Netherlands. More information on the conference can be found at www.aidsvaccine06.org
   www.aidsvaccine06.org/
2. [verwijderd] 1 september 2006 16:45

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Sanofi Pasteur Begins Shipments of Influenza Vaccine
   
   - Shipment of Fluzone Influenza Virus Vaccine to U.S. Market Begins -
   
   SWIFTWATER, Pa., September 01, 2006 /PRNewswire-FirstCall/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group, began shipping influenza vaccine (Fluzone(R), Influenza Virus Vaccine) to the U.S. market for the 2006-2007 season. The shipment represents the first of approximately 50 million doses planned for production this year.
   
   
   The most consistent and reliable supplier of injectable influenza vaccine for many years, sanofi pasteur is expected to supply approximately half of the global influenza vaccines market. This shipment will help providers start to successfully implement their immunization plans for the upcoming influenza season.
   
   As in past years, the company will use a split-delivery process so that all customers will receive at least a partial delivery of their orders by the end of September. Although this shipping process is more time consuming and costly for sanofi pasteur, the company has continued the process because it has been recognized as key to equitably distributing doses and facilitating the immunization of priority patients across the maximum number of providers.
   
   Shipments will continue until December as the company produces 50 million doses of influenza vaccine for this season. It is important to remember that the influenza season lasts from October through April, with February typically being the period of most intense disease activity. Therefore, it is still valuable to obtain an influenza vaccination in December, January and beyond.
   
   To keep pace with the nation's growing and changing immunization needs, sanofi pasteur has expanded its influenza vaccine production capability. In July 2005, construction began on a new influenza vaccine production facility in Swiftwater, Pennsylvania, that will more than double the company's U.S. capacity. The new plant is expected to come online for the 2008-2009 season.
   
   Influenza immunization is now recommended for healthy children 6 through 59 months of age. Children younger than 9 years of age receiving influenza vaccine for the first time require two doses, one month apart. The vaccine is also recommended for household contacts and out-of-home caregivers of all children younger than 24 months of age.
   
   Other groups that have been identified as being at risk for developing serious influenza-related complications include the elderly and adults and children with chronic diseases, such as asthma and diabetes. Influenza vaccination is also recommended for those 50 to 64 years of age, household contacts of at-risk individuals, and health-care workers.
   
   All other healthy individuals under 50 years of age and anyone who wishes to decrease their risk of influenza infection are also encouraged to seek vaccination.
   
   Fluzone vaccine is the only influenza vaccine licensed for populations 6 months and older. In 2004-2005, sanofi pasteur introduced a new Fluzone vaccine formulation (trade name: Fluzone(R), Influenza Virus Vaccine, No Preservative) that does not contain a preservative at any stage in the manufacturing process. It is the first FDA-licensed injectable influenza vaccine to be manufactured in this way.
   
   The 2006-2007 influenza vaccine formulation contains the A/New Caledonia/20/99 (H1N1)-like virus; an A/Wisconsin/67/2005 (H3N2)-like virus (A/Wisconsin/67/2005 or A/Hiroshima/52/2005strains); and B/Malaysia/2506/2004- like virus (B/Malaysia/2506/2004 or B/Ohio/1/2005 strains). The three strains for the new influenza vaccine formulation were confirmed by the Food and Drug Administration (FDA)'s Vaccines and Related Biological Products Advisory Committee in March 2006 and correspond with recommendations made by the World Health Organization in February. Influenza vaccine is reformulated each year to match the strains predicted to circulate in the coming season.
   
   Safety Information
   
   The most common side effects from influenza vaccine are pain and swelling at the vaccination site that can last up to two days. Some people may have mild fever, myalgia (muscle aches), or feel tired for a day or two after receiving the influenza vaccine. Other systemic reactions can occur.
   
   Injectable influenza vaccine is made from killed strains of the viruses predicted to be the main causes of influenza in the coming season. Because the viruses are killed, it is impossible to get influenza from the vaccine.
   
   People who have had previous reactions to the vaccine or people who are allergic to eggs (the viruses used in the vaccine are grown in eggs), egg products should not receive influenza vaccine. Persons allergic to thimerosal should receive a thimerosal-free version of the vaccine. Persons with acute febrile illness usually should not be vaccinated until their symptoms have abated. However, minor illnesses with or without fever do not contraindicate the use of influenza vaccine, particularly among children with mild upper respiratory tract infection or allergic rhinitis.
   
   For full prescribing information, see the package insert at www.sanofi-pasteur.us.
   
   About sanofi-aventis
   
   The sanofi-aventis Group is the world's third-largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris and in New York .
   
   Sanofi pasteur, the vaccines business of the sanofi-aventis Group, sold more than a billion doses of vaccine in 2005, making it possible to protect more than 500 million people across the globe. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. For more information, please visit: www.sanofipasteur.com
   www.engelpub.com/News/index.cfm?artic...
   
3. voda 1 september 2006 17:47

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 07 jun 2024

   • Aanbevelingen

     Ontvangen: 83930

     Gegeven: 21210

   •    Aantal posts: 367.435

   Beste Flos, wat ben je vandaag ongelofelijk actief.
   Jij vind die vernieuwde site van Crucell echt goed, he? Ik, ook.
   Groet, Voda
   
4. [verwijderd] 1 september 2006 19:41

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Succesje in strijd tegen huidkanker
   
   Amerikaanse wetenschappers zijn erin geslaagd twee patiënten met een dodelijke vorm van huidkanker succesvol te behandelen met behulp van genetisch gemodificeerde bloedcellen. Dat meldt de Britse omroep BBC.
   
   T-cellen
   De onderzoekers maakten gebruik van T-cellen, die het afweersysteem vormen. De artsen veranderden de cellen zo dat die beter waren toegerust om kanker- cellen te herkennen en aan te vallen.
   
   Proefpersonen
   De wetenschappers pasten de techniek toe bij 17 proefpersonen met melanoma, een agressieve vorm van huidkanker. Twee van hen zijn uiteindelijk genezen.
   
   Onderzoek
   Toch is nog veel meer onderzoek nodig om de doeltreffendheid van de behandeling te vergroten voordat die op grote schaal kan worden toegepast. Gentherapie, waarbij beschadigde of ziekmakende genen worden vervangen of cellen genetisch worden hergeprogrammeerd om bepaalde ziektes aan te vallen, kan mogelijk tegen veel meer ernstige aandoeningen worden gebruikt.
   
   Risico's
   Er zijn echter ook risico's. Alleen al in de Verenigde Staten zijn in de loop der jaren honderden experimenten mislukt, soms met dodelijke afloop.
   
   zie: www.rtl.nl/(/financien/rtlz/nieuws/)/...
5. [verwijderd] 1 september 2006 19:54

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   zie tevens:
   
   news.bbc.co.uk/2/hi/health/5304910.stm
   
   groetjes,
   De Oliemolen - Herman
6. zygos 1 september 2006 21:29

   auteur info

   • zygos

     Lid sinds: 23 sep 2002

     Laatste bezoek: 07 jun 2024

   • Aanbevelingen

     Ontvangen: 13

     Gegeven: 338

   •    Aantal posts: 350

   ''Crucell - Draadje OT, bijzaken & geleuter in de marge!''
   hmmm!
   mag ik hier even gebruik van maken?
   
   WK BAsket 1/2 finale:
   Griekenland - USA : 101-95
   YESSS!!
7. [verwijderd] 3 september 2006 10:36

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   03/09/2006, 2006, 08.30 AM CET
   
   New Rasilez® data highlight potential of direct renin inhibition to control blood pressure over long-term without risk of rebound[1]
   
   As monotherapy or combination therapy, once-daily Rasilez provides consistent and sustained blood pressure lowering over one year of treatment[1]
   Rasilez provides sustained 24-hour blood pressure control, with no rebound high blood pressure seen after discontinuation of therapy[1]
   Direct renin inhibitors expected to be the first new class of high blood pressure medicines available in more than 10 years
   Basel, September 3, 2006 - Novartis announced today new data showing that its direct renin inhibitor Rasilez® (aliskiren) demonstrates long-term and sustained blood pressure control without risk of rebound high blood pressure[1]. The data were presented by investigators at the 15th World Congress of Cardiology in Barcelona, Spain.
   These data add to the growing body of evidence that suggest direct renin inhibition is an effective means of controlling high blood pressure[2]. As a direct renin inhibitor, Rasilez would represent the first new treatment approach for high blood pressure in more than a decade.
   The clinical trial results presented today highlight the power of Rasilez to maintain its blood pressure lowering effect over one year of therapy. Patients in the study taking Rasilez alone or in combination with diuretic hydrochlorothiazide lowered their blood pressure substantially (-17.4/-13.3 mmHg and -18.7/-12.1 mmHg, respectively).
   These reductions were sustained over 24 hours[1] - an important treatment consideration because many high blood pressure medicines fail to provide 24-hour control. True 24-hour blood pressure control can reduce the risk of heart attacks and strokes[3].
   Interestingly, the study investigators also concluded that people in the study taking Rasilez avoided rebound high blood pressure, a potentially dangerous condition[1],[4]. After 11 months on Rasilez, some patients were switched to placebo. Despite this switch, their blood pressures rose only gradually toward baseline over the following month with no evidence of rebound[1].
   "Normally we'd expect blood pressure to quickly return to pre-treatment levels when a medicine is stopped," said Dr. Domenic Sica, Professor of Medicine and Pharmacology at the Medical College of Virginia Commonwealth University in Richmond, Virginia. "However, our study showed that this does not occur with aliskiren. This may be a benefit of directly inhibiting renin to control blood pressure."
   www.novartis.com/
8. [verwijderd] 3 september 2006 10:43

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Published online: 1 September 2006; | doi:10.1038/news060828-10
   
   I'd buy you the Moon
   
   Is it possible to buy up property in space; and should it be?
   Arran Frood
   Why not buy some land on the Moon? There seems to be plenty available on the Internet, including plots going at a bargain £14.25 per acre (plus tax and fees) from the Lunar Embassy, the company selling the 'property' of American entrepreneur Dennis Hope, who infamously claimed practically all of the Solar System in 1980 because no one else had.
   
   No one has officially recognized that Hope's lunar 'deeds' are anything more than novelty gifts. But more than 2 million have been sold since the 1980s, says the company, generating sales of millions of dollars out of empty space, leaving experts to wonder whether the commercial opportunities on the Moon might someday lead to real sales; and to suggest that perhaps they should.
   
   A growing body of financiers, lawyers and space enthusiasts believe that the recognition of personal property rights 'out there' is the only realistic way to finance the new frontier of commercially driven space exploration.
   
   Meer via www.nature.com/news/2006/060828/full/...
   
9. [verwijderd] 4 september 2006 10:10

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   =DSM verkoopt Polychemlab aan Intertek uit VK4 sep 2006, 09:53 uur
   Door Stefan Kloet
   
   Van DOW JONES NIEUWSDIENST
   
   AMSTERDAM (Dow Jones)--Chemieconcern DSM heeft zijn onderdeel Polychem Lab verkocht aan de Engelse dienstverlener Intertek, aldus Intertek maandag. Financiele details werden niet bekend gemaakt.
   
   DSM was al langer in gesprek met Intertek over een mogelijke uitbesteding van het werk bij Polychem Lab.
   
   DSM-Chief Financial Officer Arnold Gratama van Andel zei eerder dat de deal het bedrijf "miljoenen euro's" aan besparingen op zal leveren. "Het is een mooie deal. Wij besparen veel geld en Intertek kan Polychem Lab uitbreiden door nieuwe klanten te zoeken, met name in Duitsland," aldus de CFO eerder tegen Dow Jones Nieuwsdienst.
   
   Polychem Lab verleent laboratoriumdiensten aan DSM en oliemaatschappij SABIC, dat op het terrein van DSM een petrochemische fabriek exploiteert.
   
   De Engelse dienstverlener wil na de overname Polychem Lab omvormen tot een dienstverlener aan meer bedrijven dan alleen de huidige klanten. Op deze wijze wil het de omzet van Polychem Lab vergroten.
   
   - Door Stefan Kloet, Dow Jones Nieuwsdienst; +31 20 5890270, stefan.kloet@dowjones.com
   
   
10. [verwijderd] 4 september 2006 19:46

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Maryland mulls 'vaccine manufacturing capital of the world' dream
    
    By Gregory Roumeliotis
    
    
    
    
    Get the latest Market Reports on
    Maryland
    Novartis
    investment
    North Carolina
    cell culture technology
    ------------------------
    Related News
    
    Merck offers first glimpse of $300m vaccine plant
    Novartis seeks to patch up Alzheimer’s drug delivery
    -----------------------------
    North Carolina lands $600m Novartis vaccine plan
    Maryland fails to seduce Novartis
    Novartis seeks next generation of malaria drugs..!!!
    
    ----------------------
    
    31/08/2006 - Bruised by Novartis’s snub over a $600m (€466m) vaccine plant, Maryland has commissioned a study on what more the state can do to attract a major cell culture vaccine manufacturing facility there.
    
    Although the study has not yet been released, In-PharmaTechnologist.com has learned that in its findings the report suggests that the city of Baltimore and the state of Maryland will need to work much harder to attract biotech investment given the financial incentives that other states provide.
    The state had been in the running with North Carolina and Georgia for Novartis's plant, which will be the first facility in the US to use novel cell culture technology, but Aris Melissaratos, Maryland's secretary of the Department of Business and Economic Development, said that other states were willing to give away free land and so Maryland couldn't compete with that sweetener given this region's high real estate prices.
    
    Nevertheless, the state still has several firms that have committed to building manufacturing plants there, such as MedImmune and Emergent BioSolutions, yet the selection of North Carolina by Novartis stroke a raw nerve among those who have higher aspirations for Maryland.
    
    “Maryland is doing exactly what it can and should be doing to attract more biotech firms and the vaccine feasibility study is a prime example,” Morgan Wallace, of the Economic Alliance of Greater Baltimore, the organisation behind the report, told In-PharmaTechnologist.com.
    
    “Through the close working relationship that has been forged between the Maryland Department of Business and Economic Development (DBED) and Greater Baltimore's city and county economic development entities, we are constantly assessing our approach and our competitive advantages in terms of attracting biotech investment to this area.”
    
    The report however mentions areas where Maryland is lagging behind, and although officials will not go into details, it is understood that high wages, apart from financial incentives such as taxbreaks, are also weighing down on the state's competitiveness.
    
    The competitive advantage that Maryland does have in biologics R&D and production is derived from three main areas: workforce, innovation, and resources.
    
    Maryland's workforce is top-ranked for doctoral scientists and engineers with over 85,000 in the region, and home to many established biomanufacturing training programmes.
    
    As far as innovation is concerned, Maryland is unrivaled; the state has one of the largest biosciences clusters in the US, with more than 350 biotechnology companies.
    
    “The report mentions several distinct areas in which Maryland is more competitive than other states in terms of attracting biotech investment,” Wallace said.
    
    “Overall, the study reinforces why Maryland continues to rank very high in terms of biotech attraction and investment in what remains an extremely competitive environment.”
    
    In regards to specific manufacturing resources, Maryland has a wealth of good manufacturing practice (GMP) related technologies and capabilities, including a GMP training center at the University of Maryland Biotechnology Institute (UMBI) and a pilot GMP facility at the NIH's Vaccine Research Center.
    
    Still much of the report's suggestions could eventually boil down to money – according to Melissaratos, Maryland lost the Novartis plant because other states offered incentives that were five times what Maryland was prepared to offer.
    
    
11. [verwijderd] 5 september 2006 17:35

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    RFID penetration in pharmaceuticals 'rapid'
    
    By Gregory Roumeliotis
    
    
    
    Related News
    
    IBM pushes RFID for pharma
    New generation bar codes adopted by 2010
    Cost emerges as major issue in Novartis RFID trial
    Smart RFID couplings 'best way' to verify fluid line connections
    TAGSYS develops two new RFID readers
    Cardinal pioneers first-of-its-kind RFID pilot
    Millions to be made in smart pharma packaging
    
    
    Related Product Information
    Packaging machinery & supplies
    
    Related Product Newsletters
    Packaging machinery & supplies
    
    
    05/09/2006 - The market for radiofrequency identification (RFID) tags in healthcare is set to explode from $90m (€70m) in 2006 to $2.1bn in 2016, driven by the item level tagging of drugs and the growing appeal of "smart packaging."
    
    Despite the reluctance of drug manufacturers to incorporate RFID in their packaging operations, RFID guru Peter Harrop, chairman of the consultancy IDTechEx, has told In-PharmaTechnologist.com that he believes the benefits in patience compliance, fighting counterfeits and managing the supply chain will quickly prevail over the technology's costs.
    “The technology has already taken off for anti-counterfeiting in the US with about 30m RFID tags at item level, in small bottles of pills for examples, expected by end of 2006 - Viagra and Trizivir are already tagged in the US,” he says.
    
    “There is obviously huge potential as there are 10bn to 30bn yearly of prescription drugs worldwide.”
    
    RFID uptake is also fueled by patient compliance in monitoring RFID-enabled blisterpacks; there are 30,000 tags in a current US National Institute of Health (NIH) drug trial of azithromycin and a Novartis trial.
    
    These tags record which pill was taken when, the so-called smart packaging, and give the pack a unique electronic ID.
    
    Billions of them will be made every year when they are cheap enough to be used at home, something that Harrop expects in 10 to 15 years.
    
    In Europe, Stora Enso are item level tagging drugs for Orion Pharma, and the British National Health Service (NHS) has used RFID to tag medical instruments in hospitals.
    
    The primary impediments to the rollout of RFID in healthcare are limited budgets, inertia, lack of education, high cost of many RFID systems, limited number of companies providing systems integration, or "one stop shopping," and lack of trials and proven business cases for some types of application.
    
    “There is a difficulty or reluctance by big pharma to calculate the true cost of counterfeiting, drug theft and poor supply chain management, slow stocktaking by pharmacies, and other problems tackled by RFID,” he said.
    
    “Which department pays?”
    
    Barcodes are cheaper but have to be read one at a time, usually with humans involved, whereas RFID systems can count one thousand in the blink of an eye with no humans involved.
    
    Orientation, damage and obscuration are much less of a problem with RFID and it is more secure, Harrop stresses.
    
    The technology most favoured by drug companies at the moment is high frequency (HF) RFID, despite ultra high frequency (UHF) RFID being cheaper.
    
    Companies find HF more tolerant of metal and water, and, most importantly, small enough to fit on the smallest drug packages.
    
    Using silicon chips, equivalent item level tags are about one cent more expensive at HF, but if some continue to succeed in obtaining royalties under patents for UHF RFID and HF gets the cost-reduction attention paid to UHF, then that price difference may vanish, Harrop claims.
    
    “HF labels are adopted first for item level and drug compliance monitoring because they give guaranteed 99.95 per cent good reads and no ghost reads but Wal-Mart insists on UHF because it already uses this frequency for pallets and cases,” he said.
    
    “A third option touted by many suppliers but unproven in volume is 'Near Field' UHF which may give label cost lower than HF and adequate performance, the jury is out on that one.”
    
    Hissop fears there is a danger of ending up with a similar situation as with anti-theft tags, three incompatible types to go on the same items depending on the drug outlet.
    
    Decisions are urgently needed but only the US Food and Drug Administration (FDA) is showing real leadership among the regulators and even it has not finally decided, Hissop warns.
    
    
12. [verwijderd] 6 september 2006 08:16

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Persbericht Galapagos - samenwerking met OneWorld Health
    06-09-2006 08:08:23
    
    Amsterdam (BETTEN BEURSMEDIA NEWS) - Hier volgt een persbericht uitgegeven door Galapagos:
    
    Galapagos en OneWorld Health gaan geneesmiddelen tegen diarreeziekten ontwikkelen
    
    Mechelen, België en San Francisco, Californië, VS; 6 september 2006 - Galapagos NV (Euronext & LSE: GLPG) kondigt vandaag aan dat haar servicedivisie BioFocus DPI een samenwerking voor geneesmiddelen-ontwikkeling is aangegaan met OneWorld Health, een non-profit farmaceutisch bedrijf gevestigd in San Francisco. Met steun van de Bill & Melinda Gates Foundation, heeft OneWorld Health het initiatief genomen om geneesmiddelen te ontwikkelen voor verwaarloosde ziektes. De samenwerking met Galapagos concentreert zich op de bestrijding van diarreeziekten die een fundamentele bedreiging vormen voor de gezondheid van kinderen in ontwikkelingslanden. BioFocus DPI zal haar deskundigheid in medicinale chemie toepassen om nieuwe kandidaat-geneesmiddelen te identificeren tegen diarreeziekten. De totale waarde van dit contract voor Galapagos bedraagt meer dan €3 miljoen over een periode van 2½ jaar.
    
    Diarreeziekten zijn wereldwijd een belangrijke doodsoorzaak bij kinderen onder de leeftijd van vijf jaar. Elk jaar sterven meer dan twee miljoen kinderen in ontwikkelingslanden aan deze ziekten, die veroorzaakt worden door een reeks van bacteriële, parasitaire en virale ziekteverwekkers. Diarreeziekten resulteren in een snel verlies van vocht, wat tot ernstige uitdroging en de dood kan leiden. Doel van de samenwerking tussen BioFocus DPI en OneWorld Health is om geneesmiddelen te ontwikkelen die het vochtverlies in de darm remmen. Deze geneesmiddelen zullen gebruikt worden in de therapie ter behandeling van de levensbedreigende enterotoxigene E. Coli en cholera, die bijna 40% van alle diarreeziekten vertegenwoordigen. Binnen dit project zal BioFocus DPI haar medicinale chemie inzetten om kandidaat-geneesmiddelen te vinden voor verdere ontwikkeling.
    
    "Wij zijn heel trots dat OneWorld Health heeft verkozen om een project met een dergelijk gezondheidsbelang aan BioFocus DPI toe te kennen", aldus Onno van de Stolpe, CEO van Galapagos. "Deze samenwerking illustreert wederom onze capaciteiten om onze drug discovery benadering toe te passen op verschillende ziektegebieden. Het is mooi om te kunnen bijdragen aan de wereldwijde onderzoeksinspanning gericht op het redden van levens van kinderen in ontwikkelingslanden."
    
    "De deskundigheid van BioFocus DPI met het genereren van leads voor nieuwe geneesmiddelen zal een belangrijke bijdrage leveren aan ons drug development programma in diarreeziekten", aldus Dr. Victoria Hale, oprichter en CEO van OneWorld Health. "De kennis van BioFocus DPI van medicinale chemie en hun hoge onderzoeksniveau zullen ons helpen om veilige, effectieve en betaalbare geneesmiddelen te ontwikkelen voor de behandeling van diarreeziekten in ontwikkelingslanden."
    
    
13. [verwijderd] 6 september 2006 13:42

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    6/9
    --------------------------------------------------------------------------------
    Galapagos bindt strijd aan met diarreeziekten
    MECHELEN (ANP) - Het biotechnologiebedrijf Galapagos gaat samen met het Amerikaanse OneWorld Health geneesmiddelen ontwikkelen tegen diarreeziekten. Daartoe is een samenwerkingsverband gesloten, meldde Galapagos woensdag.
    
    ----------------------- en..toevallig..!?....
    6/9:
    Recent News
    
    Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial of Anti-C. difficile Antibody Combination for the Treatment of Hospital Acquired Diarrhea Sep 6, 2006
    
    Medarex to Present at the Bear Stearns 19th Annual Healthcare Conference Sep 5, 2006
    
    Medarex Announces Receipt of Notice of Default Relating to Medarex's 2.25% Convertible Senior Notes Due May 15, 2011 Aug 31, 2006
    
    Press Release Archive
    
14. [verwijderd] 6 september 2006 19:22

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hallo allemaal,
    
    Vandaag heb ik een mailtje naar de WHO gestuurd en hen gevraagd om enige info te geven mbt diverse fases van het een en ander.
    Ik zal jullie mijn gebrekkige engels besparen maar dit hebben ze me toegestuurd.
    Ik weet niet of het voor jullie oud nieuws is maar wil het jullie niet onthouden.
    
    groet,
    
    truco
    
    www.who.int/vaccine_research/document...
    
    
15. [verwijderd] 6 september 2006 21:03

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    More Than 100 Million Doses of Influenza Vaccine Expected to be Available This Year.
    
    Atlanta ,september 06,2006.The centers for disease Control and Prevention (CDC) announce today that influenza (flu) vaccine manufacturers are expexted to produce and distribute more than 100 million doses of innfluenza vaccines in the US between now and early 2007.Nanufacturers have already begun to ship this season's influenza vaccine,with almost of all of the vaccine expected to be shipped and distributed in Oktober and November.
    Dr.Julie Gerberding CDC director says -more people than ever before will be able to protect themselves and their loved ones from influenza this year.
    Manufacturers of influenza vaccine report that they expected more than 100 million of doses of influenza vaccine than has ever been distributed in the past (previous high was 83,1 million doses in 2003) and 19 million more as last year (81,2) million.
    According to the information from manufacturers ,about 75 million doses will be distributed by the end of October ,that would be 15 million more doses than were distributed by the end of october ,2005.
16. [verwijderd] 7 september 2006 14:01

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    WASHINGTON (Dow Jones)--The Centers for Disease Control and Prevention said Wednesday it expects a record 100 million influenza vaccines to be available for the 2006-2007 flu season after two years of temporary shortages and distribution problems.
    
    If projections from the four influenza vaccine manufacturers hold up, the agency does not expect to limit vaccination recommendations to those in high priority groups.
    
    Manufacturers have already begun to ship this season's influenza vaccine, with almost of all of the vaccine expected to be shipped and distributed in October and November, which is the ideal time to be vaccinated against influenza. The manufacturers are a Sanofi Aventis (SNY) unit, GlaxoSmithKline PLC (GSK), Novartis AG (NVS) and MedImmune Inc. (MEDI), which makes a vaccine that's delivered as a mist through the nose rather than a shot.
    
    "As we've learned in the past few years, there is always some uncertainty regarding influenza vaccine supplies and distribution," said Julie Gerberding, CDC director. "It's often very difficult to predict how much vaccine will be distributed and when, or exactly when influenza vaccine will be available for those who provide it."
    
    CDC said if the 100 million-plus estimate holds up, it would be about 19 million more than the 81.2 million doses distributed last year and 17 million more than the previous high distribution level of 83.1 million doses in 2003.
    
    Curtis Allen, a CDC spokesman, said recommendations on who should receive a vaccine extend to about 218 million Americans. They include anyone over age 50, people with chronic conditions such as diabetes, heart disease and asthma, children between 6 months and 5 years of age, health-care workers and care-givers of anyone in a high risk group.
    
    The agency cautioned, however, that when and how much vaccine each health-care provider or clinic receives depends on who it ordered from and when.
    
    "We expect that some health-care providers and clinics may get or have more influenza vaccine than others in the first month or so, but people will have plenty of opportunities to be vaccinated during October and November, as well as December or later," said Lance Rodewald, director of CDC's Immunization Services Division.
    
    Each year, about 5% to 20% of the U.S. population is infected with influenza. Up to 36,000 die and 200,000 are hospitalized because of influenza complications.
    
    The CDC also said people need to be vaccinated each year because the vaccines are reformulated based on three strains of influenza that are thought will be most dominant in a given year. New strains are usually chosen in February and the vaccine production and preparation process takes about six to eight months.
    
    -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com.
    
    
    (END) Dow Jones Newswires
    
    09-06-06 1414ET
    
    Copyright (c) 2006 Dow Jones & Company, Inc.
    
    
17. [verwijderd] 8 september 2006 00:28

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GSK opens vaccine plant in Hungary
    
    By Gregory Roumeliotis
    
    vaccines
    
    Related News
    
    GSK hails breakthrough bird flu vaccine
    Is big pharma killing innovation in drug formulation? - GSK defends the industry
    GSK's thirst for adjuvants grows
    GSK turns to RFID to protect its AIDS drug
    
    
    07/09/2006 - GlaxoSmithKline (GSK), a major player in vaccine manufacturing, is set to inaugurate a €100m vaccine production plant on Friday in a Hungarian city 30Km northeast of Budapest.
    
    According to a GSK spokesman, the new site in Godollo will be one of Europe's most advanced biotechnology plants and will manufacture two types of vaccines, though more details were not disclosed.
    The company employs around 360 people in Hungary and had turnover of €106.8m in 2005.
    
    GSK earlier said it plans to manufacture DPT, a combination of three vaccines to immunise against diphtheria, pertussis and tetanus, at the Godollo plant.
    
    The drugmaker plans output in the order of 100m units a year to cover its entire world-wide needs.
    
    GSK was responsible for about a quarter of the $11bn (€8.6bn) of vaccine sales across the world last year, and expects to launch five major new vaccines over the next five years, including an improved flu vaccine for the elderly and a new meningitis treatment for infants.
    
    
18. [verwijderd] 8 september 2006 10:12

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    RTRS-DSM bouwt twee fabrieken in Geleen - UPDATE
    N i e u w bericht, meer informatie
    
    GELEEN (ANP) - DSM steekt 100 miljoen euro in de bouw van
    twee nieuwe fabrieken op zijn industrieterrein Chemelot in
    Geleen. Het chemieconcern wil de productie van grondstoffen voor
    onder meer de vezel Dyneema verdubbelen. Dat heeft DSM vrijdag
    bekendgemaakt.
    
    De vezel Dyneema wordt gebruikt in onder meer zware
    afmeerkabels voor schepen, allerlei sporttoepassingen, maar ook
    in snijbestendige kleding tegen terrorisme. Volgens DSM is het
    plastic draad vijftien keer sterker dan hoogwaardig staal. De
    fabrieken zullen volgens plan in 2008 draaien.
    
    De investering past binnen het nieuwe vijfjarenplan (Vision
    2010) van het Limburgse concern om zijn positie in hoogwaardige
    materialen te versterken. De materialen van DSM worden onder
    meer gebruikt in de automobielindustrie, in mobiele telefoons en
    in computers.
    
    DSM was de laatste jaren vooral bezig met bezuinigingen in
    Geleen. Velen in de regio vreesden voor meer ontslagen. Volgens
    directeur Frans Pistorius van DSM Nederland bewijst de vrijdag
    aangekondigde investering echter dat DSM belang hecht aan zijn
    thuisbasis. ,,De investeringen betekenen een nieuwe stimulans
    voor de locatie en voor de economische groei in de regio'',
    aldus Pistorius.
    
    ((Maarten Dijksma, email economie(at)anp.nl, +31 20 504
    5999))
    
19. [verwijderd] 8 september 2006 13:56

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Cancer's Genetic Code Cracked
    Thursday, September 07, 2006
    By Daniel J. DeNoon
    
    Scientists say they have cracked the genetic code of breast and colon cancers, letting them "study the enemy's game plan.”
    The breakthrough comes from a huge effort led by researchers at Johns Hopkins Kimmel Cancer Center. It's not the first-ever look at cancer genes. But it's the first time scientists have used 21st-century technology to scan the entire genome of breast and colon cancers, says Will Parsons, MD, PhD.
    Parsons, a Johns Hopkins and National Cancer Institute researcher, is a member of the research team, which includes Victor E. Velculescu, MD, PhD; Bert Vogelstein, MD; and Kenneth W. Kinzler, PhD, of Johns Hopkins.
    "We already know that cancer is the result of a series of mutations in normal cells," Parsons tells WebMD. "Now we have a blueprint for how that works."
    How important is this finding?
    It's not going to help people now suffering from cancer. But for researchers trying to find future cancer treatments, this is very big news. That's why Elias A. Zerhouni, MD, director of the National Institutes of Health, calls the findings "truly remarkable" and "groundbreaking."
    
    Meer via:
    www.webmd.com/content/article/127/116...
    www.sciencemag.org/cgi/data/1133427/D...
    www.hhmi.org/news/vogelstein20060908....
    www.washingtonpost.com/wp-dyn/content...
20. [verwijderd] 8 september 2006 14:12

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Blauwtongziekte duikt op in Friesland
    Bij twee dieren op een verzamelcentrum bij Leeuwarden is de blauwtongziekte vastgesteld.
    
    Regime
    De nieuwe gevallen zijn niet afkomstig uit Zuid-Limburg, waar het virus half augustus voor het eerst werd geconstateerd. Het ministerie van Landbouw stelde direct een nieuw regime voor blauwtong in. In het hele land gelden nu gelijkwaardige regels.
    
    Besmettingen
    Minister Veerman adviseert verder in het noorden dieren 's avonds op te stallen en insecticiden te gebruiken. Het aantal besmette bedrijven in het zuiden is inmiddels tot 38 gestegen.